Tuesday, May 30th, OWCP put out an 8K with the headline that they’ve “Entered Into a Strategic Relationship With Germany-Based mediq Innovation Experts”.
First thing I did was look to their website for more details about who they are. Turns out they’ve been in business for 10 years — which I could also confirm by seeing that they bought their domain name back in 2007.
The 8K starts by stating that the purpose of this agreement was to introduce the Psoriasis Cream to the German market. They go onto telling us that mediq “has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets. mediq’s objectives for OWCP will consist of both scientific collaboration and most importantly the development of a commercial market for OWCP’s proprietary, active cannabinoid-based topical psoriasis cream in Germany.”
Jan Wende, managing director of mediq stated, “We are looking forward to initiating our efforts on behalf of OWCP in Europe, starting in our home market of Germany. Since German laws and regulations allow non-smokable forms of medical cannabis, we believe that OWCP’s proprietary cannabinoid-based topical psoriasis cream is the right product at the right time. Furthermore, Germany is the largest European healthcare market and therefore offers the perfect platform to gain local evidence and roll out the concept into other European countries. Our initial focus for OWCP is on the German market, however we’re excited about the long-term opportunities throughout Europe, a market with a population of over 740 million.”
Alon Sinai, OWCP Managing Director, went onto say, “The German market is a great opportunity for OWCP. Germany, with its population of over 81 million, and a gross domestic product of over US$3.36 trillion is the largest economy in Europe. Also, potentially beneficial to OWCP is Germany’s recent medical cannabis legislation, which currently limits the usage of smokable-products, and which also provides for reimbursement for medical cannabis by the country’s healthcare system. mediq is a great partner for OWCP, and we’re looking forward to the prospects of a long-term and mutually relationship with the company both regarding the introduction of OWCP’s cannabinoid-based psoriasis cream in the German marketplace, but also for the prospects for scientific collaboration in the country.”
At that point, the 8K typically just breaks down the generic “about” info for OWCP and then mediq, but they do remind us about the 70% improvement in a variety of inflammation markers with the Psoriasis Cream.
Tomorrow, we should see much better volume. I absolutely feel there’s more news coming in June, as there are many things the company needs to update shareholders on once they’ve had a chance to execute.
Patience, folks. It will pay. (In my honest opinion, of course.)
Thanks for your honest opinion. It is so refreshing. I have given up on InvestorsHub. I worked very hard for the money I invested in OWCP and am sick of the bashers. I know there is nothing guaranteed but I am long with this stock and a true believer.
Yeah! One giant step for OWCP-kind. Long and strong!
MedIQ is Legit and HCTC Alliance is the REAL DEAL:
https://www.pressebox.de/pressemitteilung/inline-sales-gmbh/Hannover-Clinical-Trial-Center-MedIQ-Innovation-Experts-and-The-Channel-Group-form-an-International-Life-Sciences-and-Biomedical-Alliance-Support/boxid/837480
Hannover Clinical Trial Center (HCTC) and its long time business partner MedIQ Innovation Experts GmbH (MedIQ) have formed an affiliation with The Channel Group, LLC (TCG) in New York to provide access to advisory support around the globe.
Key points from the HCTC Alliance news release MedIQ released February this year.:
1. Through the alliance the partners offer international clients a range of advisory and transactional services.
2. HCTC and its partner MedIQ) provide premarket strategic analysis, clinical, regulatory and commercial development, market entry strategy, and management services to companies planning to enter the European market.
3. Hannover Clinical Trial Center, founded in 2005, is an academic Contract Research Organization dedicated to provide clinical trial management services and early product development support.
4. HCTC overseas more than 50 active clinical studies.
About MedIQ Innovation Experts:
MedIQ is a strategy and innovation consulting firm for the German, European and Israel markets. The company specializes in supporting strategic vision, clinical validation, market assessment and development, for companies focused on approval and commercialization of biomed/lifescience products into the European market.
About The Channel Group:
The Channel Group, founded in 2002, provides strategic advisory support to the Biomedical and Life Sciences sectors that is focused on transaction and transitional activities. Having served as executive management in healthcare companies from startups to Fortune 500 companies
About the Affiliation
The Channel Group, MedIQ Innovation experts and HCTC recognize that companies in the US and Europe require significant support in their desire to access markets in Europe and North America.
Wow, that’s great bonus DD. Thanks Richard!
excellent! Germany soon and more in Europe to come..owcp on its way..and this is just the beginning…